Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer
Xiaofei Zhang,Tiebo Mao,Bei Zhang,Haiyan Xu,Jiujie Cui,Feng Jiao,Dongqin Chen,Yu Wang,Jiong Hu,Qing Xia,Weiyu Ge,Shumin Li,Ming Yue,Jingyu Ma,Jiayu Yao,Yongchao Wang,Yanling Wang,Daiyuan Shentu,Xiao Zhang,Shiqing Chen,Yuezong Bai,Yuexiang Wang,Xuebin Zhang,Qiang Liu,Yongwei Sun,Deliang Fu,Yingbin Liu,Lei Xiong,Liwei Wang
DOI: https://doi.org/10.1016/j.ebiom.2022.103897
IF: 11.205
2022-03-01
EBioMedicine
Abstract:BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a malignant tumor with an extremely poor prognosis. Effective targets for anticancer therapy confirmed in PDAC are limited. However, the characteristics of genomics have not been fully elucidated in large-scale patients with PDAC from China.METHODS: We collected both blood and tissue samples from 1080 Chinese patients with pancreatic cancer and retrospectively investigated the genomic landscape using next-generation sequencing (NGS).FINDINGS: We found recurrent somatic mutations in KRAS (83.2%), TP53 (70.6%), CDKN2A (28.8%), SMAD4 (23.0%), ARID1A (12.8%) and CDKN2B (8.9%) in Chinese PDAC patients. Compared with primary pancreatic cancers, more genomic alterations accumulated especially cell cycle regulatory gene variants (45.4% vs 31.6%, P < 0.001) were observed in metastatic tumors. The most common mutation site of KRAS is p.G12D (43.6%) in pancreatic cancer. Patients with KRAS mutations were significantly associated with older age and mutations in the other three driver genes, while KRAS wild-type patients contained more fusion mutations and alternative mechanisms of RTK/Ras/MAPK pathway including a number of clinically targetable mutations. KRAS mutations in Chinese cohort were significantly lower than those in Western cohorts (all P < 0.05). A total of 252 (23.3%) patients with the core DNA damage response (DDR) gene mutations were detected. ATM (n =59, 5.5%) was the most frequent mutant DDR gene in patients with pancreatic cancer from China. Patients with germline DDR gene mutations were younger (P = 0.018), while patients with somatic DDR gene mutations were more likely to accumulate in metastatic lesions (P < 0.001) and had higher TMB levels (P < 0.001). In addition, patients with mutant DDR genes and patients carrying TP53 mutation were observed mutually exclusive (P < 0.001).INTERPRETATION: We demonstrated the real-world genomic characteristics of large-scale patients with pancreatic cancer from China which may have promising implications for further clinical significance and drug development.FUNDING: The funders are listed in the Acknowledgement.
medicine, research & experimental